Advertisement
Interested parties may access a live audio webcast of the presentation viathe investor section of the BioMarin website, http://www.BMRN.com. A replayof the presentation will be archived on the site for at least one weekfollowing the presentation.
Advertisement
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals forserious diseases and medical conditions. The company's product portfoliocomprises three approved products and multiple clinical and preclinicalproduct candidates. Approved products include Naglazyme(R) (galsulfase) formucopolysaccharidosis VI (MPS VI), a product wholly developed andcommercialized by BioMarin; Aldurazyme(R) (laronidase) formucopolysaccharidosis I (MPS I), a product which BioMarin developed through a50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterindihydrochloride) Tablets, a product for the treatment of phenylketonuria(PKU), developed in partnership with Merck Serono, a division of Merck KGaA ofDarmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascularindications, which is currently in Phase 2 clinical development for thetreatment of peripheral arterial disease and sickle cell disease, and PEG-PAL(PEGylated recombinant phenylalanine ammonia lyase), which is currently inPhase 1 clinical development for the treatment of PKU. For additionalinformation, please visit http://www.BMRN.com. Information on BioMarin'swebsite is not incorporated by reference into this press release.
BioMarin(R), and Naglazyme(R) and Kuvan(R) are registered trademarks ofBioMarin Pharmaceutical Inc.Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-6594
SOURCE BioMarin Pharmaceutical Inc.